FOLH1 and metastatic neoplasm: In addition to biochemical recurrence following definitive therapy, the two PSMA targeting tracers, [18F]-PSMA and [68Ga]-PSMA, are also FDA approved for up-front assessment of metastatic disease in men eligible for definitive treatment.